Open AccessA case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma
Author(s) -
Wallace Natalie,
Wong Ellice,
Cooper Dennis,
Chao Herta
Publication year - 2016
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.719
Subject(s) - ibrutinib , medicine , mantle cell lymphoma , cardiomyopathy , cardiology , lymphoma , ventricular tachycardia , tachycardia , heart failure , oncology , leukemia , chronic lymphocytic leukemia
Key Clinical Message Ibrutinib is a first‐in‐class inhibitor of Bruton's tyrosine kinase, which is approved for use in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Although ibrutinib has been linked to an increased incidence of atrial fibrillation, this is the first report of an association with nonischemic cardiomyopathy and ventricular arrhythmia.